NCT05061277撤回1 期
A PHASE 1, OPEN-LABEL, SINGLE SUBCUTANEOUS DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF LYOPHILIZED FORMULATION OF RECIFERCEPT IN HEALTHY CHINESE PARTICIPANTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Pfizer
- 试验地点
- 1
- 主要终点
- Area Under the Serum Concentration Time Profile from Time Zero to 168 hrs (AUC0-168)
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetic (PK), safety, tolerability and immunogenicity of a single subcutaneous (SC) dose of the lyophilized formulation of recifercept in healthy Chinese participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Chinese male and female participants of nonchildbearing potential must be 21 to 55 years of age, inclusive at the time of signing the ICD.
- •Chinese male and female participants who are overtly healthy as determined by medical evaluation.
- •Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- •Participants must be of Chinese ethnicity (individuals currently residing in mainland China who were born in China and have both parents of Chinese descent).
- •Body mass index (BMI) of 19.0 to 27.5 kg/m2; and a total body weight >50 kg and ≤ 120 kg.
- •Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, skin inflammation at infusion site, acne, rash, scarring, tattoos, erythema, sunburn, deep tanning, etc).
- •History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), or serological reaction of syphilis. Prior hepatitis B vaccination is allowed.
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- •Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half lives (whichever is longer) prior to the dose of study intervention.
- •Previous administration with an investigational drug/medical device within 30 days (or as determined by the local requirement) or 5 half lives preceding the dose of study intervention used in this study (whichever is longer).
- •A positive urine drug test.
- •Screening supine blood pressure (BP) ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. Pulse rate > 100 beats/minute. Oral temperature (or ear temperature) > 37.5 ℃.
- •Baseline 12 lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline corrected QT (QTc) interval >450 msec, complete LBBB, signs of an acute or indeterminate age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second or third degree AV block, or serious bradyarrhythmias or tachyarrhythmias).
- •Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
- •aspartate aminotransferase (AST) or aspartate aminotransferase (ALT) level ≥ 1.5 × upper limit of normal (ULN);
- •Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is≤ ULN.
研究组 & 干预措施
Recifercept
Experimental
A 300 mg single subcutaneous (SC) dose of recifercept for the treatment phase of study
干预措施: Recifercept (Drug)
结局指标
主要结局
Area Under the Serum Concentration Time Profile from Time Zero to 168 hrs (AUC0-168)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168 hours post-dose
Time for Cmax (Tmax)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Area Under the Serum Concentration Time Profile from Time 0 Extrapolated to Infinite Time (AUCinf)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Terminal Elimination Half-Life (t½)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Maximum Observed Concentration (Cmax)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Apparent Clearance (CL/F)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
Apparent Volume of Distribution (Vz/F)
时间窗: 0, 2, 4, 6, 12, 24, 48, 72, 120, 168, 216, 264, 312, 504 hours post-dose
次要结局
- Incidence of Participants With Positive Neutralizing Antibodies (NAb)(Maybe 0, 168, 312, 504, 672 hours post-dose and maybe months 4 and/or month 7 post-dose)
- Incidence of Participants With Clinically Relevant Changes in 12-lead Electrocardiogram (ECG)(Baseline, within -3 hours pre-dose, and at 4, 24, 48, 72 hours post-dose, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Positive Anti-Drug Antibodies (ADA)(0, 168, 312, 504, 672 hours post-dose and maybe months 4 and/or month 7 post-dose)
- Incidence of Adverse Events (AEs)(Since inform consent form (ICD) is signed till up to about Day 29, or maybe till Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Clinically Relevant Changes in Vital Signs(Baseline, within -3 hours pre-dose, and at 4, 24, 48, 72 hours post-dose, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Participants With Infusion Site Reactions(From time of signing inform concent form (ICD) to approximately Day 29, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withdrawal from study)
- Incidence of Clinical Laboratory Test Abnormalitiests(Baseline to approximately Day 22, or up to approximately Month 4 or Month 7 post-dose, or when terminated/withwal from study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study of M5049 in Healthy Japanese and Caucasian ParticipantsHealthyNCT04880213Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany36
已完成
1 期
Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532HealthyType 2 Diabetes MellitusNCT01369602Pfizer27
进行中（未招募）
1 期
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIVHIV InfectionsNCT06652958ViiV Healthcare102
已完成
1 期
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of BalcinrenoneHepatic ImpairmentNCT06388616AstraZeneca30
已完成
1 期
A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy VolunteersNASHNCT03207425Enanta Pharmaceuticals, Inc29